Parul Bhandari - 23 Jun 2026 Form 4 Insider Report for NRC HEALTH (NRC)

Reporting relationship: Director
Issuer ticker: NRC
Reported as of: 23 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jun 2026, 16:42:39 UTC
Prior SEC filing: 17 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Parul Bhandari, by Christopher Kortum, attorney-in-fact, pursuant to a POA previously filed with the SEC

Key filing fact

Parul Bhandari filed Form 4 for NRC HEALTH (NRC) on 25 Jun 2026.

Key facts

This page summarizes Parul Bhandari's Form 4 filing for NRC HEALTH (NRC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jun 2026, 16:42.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001861355 Primary reporting owner

Bhandari Parul

Relationship: Director
Address: C/O NRC HEALTH, 1245 Q STREET, LINCOLN
Signature: /s/ Parul Bhandari, by Christopher Kortum, attorney-in-fact, pursuant to a POA previously filed with the SEC
Signature date: 25 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRC transaction

Common Stock

Award

Transaction value
Shares: +7,697
Change %
Price: $0.000000^*
Shares after: 7,697
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.